- Clone:
- REA401 | 330G5
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- ICFC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for MLC2v Antibody, anti-human/mouse/rat, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated MLC2v (REA401) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
Clone REA401 recognizes the human, mouse, and rat ventricular isoform of the myosin light chain 2 (MLC2v) antigen. Myosin is a hexamer composed of two myosin heavy chains and four myosin light chains. In the heart two different forms of the myosin light chain are expressed, the atrial form (MLC2a) and the ventricular form (MLC2v). MLC2v is restricted to the ventricular segment of the heart tube at embryonic day 8 in rodents, suggesting that its ventricular specification occurs relatively early during mammalian cardiogenesis. In contrast, the atrial isoform of the myosin light chain 2 (MLC2a) is expressed in the presumptive ventricle prior to MLC2v, and its ventricular expression is subsequently down-regulated. In the fetal stage, MLC2a is primarily found in the atria while MLC2v is essentially restricted to the ventricles, albeit low levels of both MLC2a and MLC2v persist in the inflow tract, the atrioventricular canal and the outflow tract of the heart. MLC2v may as well be suitable to identify mouse and human pluripotent stem cell-derived cardiomyocyte subtypes.
Additional information: Clone REA401 displays negligible binding to Fc receptors.
MYL2, CMH10, MLC2, MLC-2v
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
You have previously chosen International as your location.
What do you want to do?